BioPharma Reporter

DECEMBER 6, 2021

Trince, a spin-off of Ghent University (UGent) that is focused on advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo, has raised â4m from investors.

In-Vivo 90

In-Vivo In-Vitro Development 90

Pharmaceutical Technology

NOVEMBER 9, 2022

The collaboration project will evaluate the tumoricidal effects in an orthotopic mouse model and the advantages of LB-1 in-vivo nanoparticle-based administration. The collaboration project will evaluate the tumoricidal effects in an orthotopic mouse model and the advantages of LB-1 in-vivo nanoparticle-based administration.

In-Vivo 130

In-Vivo Development In-Vitro Scientist 130

BioSpace

FEBRUARY 18, 2021

NKarta Therapeutics is using engineered chimeric antigen receptor natural killer T cells (CAR-NKT cells) for allogeneic therapy, showing substantial benefits both in vitro and in vivo, according to James Trager, CSO, speaking Wednesday at the virtual CAR-TCR Summit – Europe.

In-Vivo 106

In-Vivo In-Vitro Engineer 106

Pharmaceutical Technology

MAY 5, 2023

TFF Pharmaceuticals and NIEHS will investigate the TFF-HMW-HA formulations’ therapeutic efficacy and pharmacokinetics using in vitro and in vivo models of respiratory diseases.

Development 162

Development In-Vivo In-Vitro Engineer 162

Scienmag

JUNE 29, 2021

Oncotarget published “High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC” which reported that the aim of […].

In-Vivo 96

In-Vivo In-Vitro Protein Medicine 96

XTalks

APRIL 14, 2022

Conventional in vitro and in vivo studies are used in the drug development pipeline. However, could there be another way for developing biomedical products using in silico technology? This involves the use of an individualized computer simulation for medical device or drug development. Want to learn more?

Trials 98

Trials In-Vivo In-Vitro Clinical Trials 98

Drug Discovery World

APRIL 24, 2024

Andrew Farnum, CEO at Variant Bio, added: “Evotec has established and validated in vitro and in vivo models to accelerate programme timelines and is ideally positioned to advance our fibrosis programme. Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.

Development 52

Development In-Vivo In-Vitro Genome 52

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

OCTOBER 4, 2023

Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. This on-demand webinar shows how cloud implementation fosters accessibility and collaboration, revolutionising research across locations and companies.

Drugs 52

Drugs In-Vivo In-Vitro Research 52

Pharmaceutical Technology

OCTOBER 5, 2022

Autologous CAR-T therapy does not easily lend itself to treating CLL, as it relies on extracting functional T-cells from the patient’s blood and genetically modifying them in vitro. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.

In-Vitro 279

In-Vitro In-Vivo Sales Clinical Trials 279

Pharmaceutical Technology

NOVEMBER 4, 2022

The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise. The staff in the US from the acquired business will be retained by Reaction to set up its presence in Hershey, which comprises in vitro and in vivo expertise.

In-Vivo 130

In-Vivo In-Vitro Genetics Drugs 130

Drug Discovery World

NOVEMBER 15, 2022

Discover how in vitro assays can be used to model in vivo neurodegeneration. Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain. Learn how to select the most appropriate assay for your drug target of interest.

In-Vitro 52

In-Vitro In-Vivo Drugs Life Science 52

Drug Discovery World

OCTOBER 4, 2023

Watch this new webinar to embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery.

In-Vivo 52

In-Vivo In-Vitro Drugs Research 52

Drug Discovery World

NOVEMBER 15, 2022

Discover how in vitro assays can be used to model in vivo neurodegeneration. Discover how in vitro assays can be used to model in vivo neurodegeneration. Neurodegenerative diseases are characterised by neuronal damage, degradation of the blood-brain barrier and failures in the normal repair mechanisms of the brain.

In-Vitro 52

In-Vitro Drugs In-Vivo Life Science 52

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

Drug Discovery World

JUNE 8, 2023

Grown in vitro, these cells can provide patient specific human brain models from a large cohort of AD patients – to create a ‘clinical trial in a dish’. sAD has no specific family link and is caused by a combination of genetics, the environment and a person’s lifestyle.

Clinical Trials 97

Clinical Trials Clinical Trials Trials In-Vitro 97

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

Drug Discovery World

JUNE 26, 2023

Select monoclonal IgG4 antibodies, re-engineered from human IgE antibodies, were able to inhibit allergic plasma IgE from binding recombinant Ara h 2 in vitro, and also inhibit whole peanut-mediated mast cell and basophil activation. IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies.

Allergies 52

Allergies Antibody In-Vivo In-Vitro 52

Drug Discovery World

OCTOBER 25, 2023

Data generated by our laboratory across in vitro and in vivo models and from human clinical samples support this important finding. Previous attempts to interrupt TGF-β pathway signaling in cancer have been thwarted by activation of alternative resistance pathways by the tumour.

Research 52

Research In-Vivo In-Vitro Clinical Development 52

BioTech 365

OCTOBER 25, 2021

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting – In vitro and in vivo studies show mechanisms for antitumor activity … Continue reading →

In-Vivo 52

In-Vivo In-Vitro 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Innovation S-curve for artificial Intelligence in the pharmaceutical industry In-silico drug discovery is a key innovation area in artificial Intelligence Drug research starts with the discovery stage that involves in vivo and in vitro models to shortlist lead drug compounds.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Drug Discovery World

JANUARY 25, 2024

The research will include studies to assess the effects of Vaxxinity’s active immunotherapies on undisclosed proteins implicated with bone and muscle growth through in vitro and in vivo experiments, and animal models established by UCF.

Medicine 52

Medicine Research In-Vivo In-Vitro 52

Pharmaceutical Technology

MAY 24, 2023

It is building many MDSC-targeted, bi-functional ADCs for in vitro and in vivo characterisation, with lead selection expected by the end of next year. Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0, The company is also advancing its mRNA vaccine, IFx-Hu3.0,

Gene Therapy 130

Gene Therapy In-Vivo In-Vitro Immune Response 130

Scienmag

FEBRUARY 17, 2021

In particularly, the use of RE luminescent materials for in vitro and in vivo imaging can easily […].

In-Vivo 52

In-Vivo In-Vitro 52

BioTech 365

MARCH 9, 2021

an important non-canonical DNA secondary structure in vivo and in vitro, G-quadruplexes (GQs) have been widely investigated in many fields including biology, … Continue reading →

Scientist 40

Scientist In-Vivo In-Vitro DNA 40

Drug Discovery World

AUGUST 3, 2023

Founded in 2011, the company delivers discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology. This is the third acquisition by Sygnature over the last sixteen months, following the investment by Five Arrows in Summer 2021.

In-Vivo 52

In-Vivo In-Vitro Protein Marketing 52

Drug Discovery World

FEBRUARY 13, 2024

It has demonstrated efficacy in in vitro and in vivo models of fibrosis, as well as favourable safety and pharmacokinetic profiles in Phase I clinical studies. It has demonstrated efficacy in in vitro and in vivo models of fibrosis, as well as favourable safety and pharmacokinetic profiles in Phase I clinical studies.

Drugs 52

Drugs In-Vivo In-Vitro Medicine 52

Drug Discovery World

MARCH 26, 2024

We were excited to unveil data showing that two distinct chemical series exhibit METTL1 inhibition in vitro at low nanomolar concentrations with minimal interference with other RNA and protein methyltransferases. In vivo, METTL1 inhibitors induce tumour growth inhibition in both immune-deficient and immune-competent mouse strains.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

APRIL 25, 2023

Download our mitochondrial toxicity infographic and discover the benefits of novel in vitro strategies for consumer safety. Learn about new in vitro methods that can easily be incorporated into your drug safety workflow. Our infographic will help you: Gain an historical perspective on mitochondrial toxicity.

In-Vitro 52

In-Vitro Drugs Marketing In-Vivo 52

Drug Discovery World

APRIL 25, 2023

Download this new mitochondrial toxicity infographic by Agilent and discover the benefits of novel in vitro strategies for consumer safety. Learn about new in vitro methods that can easily be incorporated into your drug safety workflow. The infographic will help you: Gain an historical perspective on mitochondrial toxicity.

In-Vitro 52

In-Vitro Drugs Marketing In-Vivo 52

Drug Discovery World

JUNE 27, 2023

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. We are thrilled to continue this collaboration as part of our mission to advance impactful agents into the clinic.”

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

Drug Discovery World

APRIL 21, 2023

The results showed NT219 induced significant PDL1 expression in melanoma cells in-vitro and showed a synergistic effect with anti-PD1 therapy in tumour growth inhibition in-vivo. Purple Biotech shared the new results at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Florida, US.

Drugs 98

Drugs In-Vivo In-Vitro Protein 98

Drug Discovery World

JANUARY 3, 2023

Merck KGaA will be solely responsible for in vitro and in vivo characterisation, other preclinical work, and all clinical development and potential commercialisation activities relating to any resulting product candidates. . Mersana will receive an upfront payment of $30 million.

Antibody 52

Antibody Development Research Drugs 52

Drug Discovery World

JANUARY 31, 2024

Support for danegapitide’s potential With safety data derived from over 500 clinical trial participants, robust toxicology data, and strong non-clinical in vitro and in vivo efficacy results, there is strong support for danegaptide’s potential to address the clinical core ocular pathologies of vascular leakage and capillary breakdown.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vivo In-Vitro 52

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Trials 52

Trials In-Vivo In-Vitro Antibody 52

Drug Discovery World

JUNE 6, 2023

In preclinical studies conducted by the company, BEN-34712 was neuroprotective in a patient-derived, disease-relevant in vitro motor neuron/iAstrocyte co-culture model, demonstrating significant efficacy in both sporadic and familial subtypes of ALS.

Drugs 52

Drugs In-Vivo In-Vitro Clinical Development 52

Drug Discovery World

JUNE 19, 2023

Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. This investment from the AFB FII fund stems from the AdBio-Inserm Transfert partnership announced in May 2022 to finance, support and grow Europe’s most innovative life science startups.

Development 52

Development Life Science In-Vivo In-Vitro 52